Dataset from A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)

The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or
VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free
survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic)
biliary tract cancer.